2019 CCRM Australia – WAHTN Technology Evaluation Workshop

WAHTN in partnership with the Centre for Cell Therapy and Regenerative medicine (CCTRM) and the Centre for Commercialisation of Regenerative Medicine (CCRM) Australia are happy to announce the 2019 CCRM Australia – WAHTN Technology Evaluation Workshop.


The Workshop coincides with the visit of the Canadian CEO of CCRM, Dr Michael May, who will be visiting Perth in May this year. Dr May will be in attendance at the Workshop and will be able to provide feedback on participant presentations. In previous Technology Evaluation Workshops participants have received valuable feedback from Dr May, and in some cases, participants have been referred to other contacts in the same research area.


CCRM is a leading Canadian not-for-profit which develops new cutting edge technologies in the field of regenerative medicine, including cell and gene therapy.


While CCRM are open to new technologies which advance the field of regenerative medicine, the following are also of interest:


Cell and gene therapy:

  • T cell immunotherapies (CAR-T), target discovery platforms, and biomarkers to identify potent T cell subsets
  • Generation of universal antigen specific T-cells
  • Genetic modifications for enhanced cell targeting
  • Exosomes-based delivery of therapeutics
  • Cardiac/neural cell therapies
  • Small molecules for endogenous repair
    • Small molecule and mimetic alternatives to protein factors (e.g. growth factors) to be used for manufacturing
    • Novel defined (recombinant proteins only) medium formulations for production of commercially relevant cell types
  • Gene therapy approaches


Enabling Technologies:

  • Human PSC differentiation
  • Label-free cell isolation
  • Gene/epigenome editing and non-viral delivery
    • Cell engineering (genetic switches, rapid clone selection, hot-swappable regions, integration site targeting, expression stability, etc)
  • Lentiviral transfection and transduction
    • High-efficiency cell transduction (e.g. process related or new LVV envelope proteins)
  • AAV for targeted delivery including novel AAV capsids



  • Non-enzymatic passaging of cells in bioreactors
  • New bioreactor technologies relevant to manufacture of commercially relevant cell types
    • High efficiency volume reduction and washing, should be scalable (e.g. from 1L scaled to a magnitude of 100 or more)
  • Virus filtration/clarification/isolation methods (LVV and AAV)
    • High efficiency and high purity continuous enrichment of virions (lentivirus and AAV) from cell culture broth
  • Rapid assays for quantification of functional viral titre (lentivirus and AAV) new approaches to support manufacturing workflow i.e.:
    • Tracking technologies (materials, equipment, products and people)
    • Process data capture/monitoring and interrogation
    • Procedural tracking
    • Process modelling and scheduling
  • Media development and formulations
    • New algorithms/methods for efficient exploration of high dimensional design spaces in media development and culture optimisation
    • Low cost, high efficiency, scalable cell enrichment
  • Sensors to measure cell viability and biomass:
    • In-reactor analysis of media composition (metabolites, proteins, physico-chemical parameters)
    • In-reactor or rapid at-line and automated analysis of cell phenotype
      • In both cases preferably g-irradiation stable and single use
  • Rapid assays for detection of microbiological contamination


Event Details:

Date: Thursday 23 May 2019

Time: 14:30 – 16:30

Location: McCusker Auditorium, the Harry Perkins Institute of Medical Research (North)

Bookings are essential and will fill up fast. Place yours now